| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |